logo
Share SHARE
FONT-SIZE Plus   Neg

Eli Lilly Says Dulaglutide Meets Primary Endpoint - Quick Facts

Eli Lilly and Co. (LLY) announced that dulaglutide, its investigational, long-acting glucagon-like peptide 1, or GLP-1, analog being studied as a once-weekly treatment for type 2 diabetes, met its primary endpoint of non-inferiority for mean 24-hour systolic blood pressure after 16 weeks.

According to the company, the results came from a Phase II study that compared two doses of dulaglutide to placebo, using ambulatory blood pressure monitoring to characterize changes in blood pressure and heart rate. Also, the 1.5 mg dulaglutide dose significantly reduced mean 24-hour SBP compared to placebo.

Gwen Krivi, vice president, product development, Lilly Diabetes, said, "We are very encouraged by these clinical trial results, in addition to the rest of the clinical trial data we've seen to date for dulaglutide. Dulaglutide is currently in Phase III clinical trials, where it will continue to be evaluated on its efficacy to lower blood glucose levels, overall safety, weight effects and effects on cardiovascular outcomes. We believe dulaglutide, if approved, can bring significant benefits to people with type 2 diabetes."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Kingfisher Plc were declining around 7 percent in the morning trading in London after the home improvement retailer reported Wednesday weak sales in its first quarter on a constant currency and like-for-like basis amid continued weaker sales in France. On a reported basis, sales increased from last year. Shares of U.S. grains trader Bunge Ltd. climbed around 17 percent on Tuesday after the Swiss mining giant Glencore Plc confirmed that its agriculture joint venture has made an informal takeover approach. Bunge, meanwhile, said its not engaged in business combination talks with Glencore or its JV Glencore Agriculture Limited. A United Airlines flight from Shanghai to New Jersey was delayed for hours as an unruly passenger refused to vacate the seat of another passenger while boarding the aircraft in Shanghai. The flight was also forced to make an unscheduled stop at San Francisco International Airport to get a replacement crew after delays caused by the passenger.
comments powered by Disqus
Follow RTT